Novartis Aims Canakinumab At Targeted CV Patients

New CANTOS analyses show that the "lower is better" mantra applies to inflammation as well as LDL-cholesterol. Novartis hopes they will lead canakinumab to becoming the first targeted anti-inflammatory therapy for heart attack patients, but hurdles lie ahead.